Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have received a consensus rating of “Buy” from the fourteen research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $117.8182.

Several equities research analysts recently commented on the stock. HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 9th. Oppenheimer upped their price target on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research report on Monday, March 9th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Truist Financial upped their price target on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 9th.

Insider Activity at Dianthus Therapeutics

In related news, CEO Marino Garcia sold 122,918 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Simrat Randhawa sold 33,830 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 349,551 shares of company stock worth $28,968,156 in the last quarter. Company insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of DNTH. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $27,000. First Horizon Corp purchased a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $40,000. Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $64,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after buying an additional 3,317 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Down 1.0%

Shares of DNTH opened at $84.13 on Friday. The firm has a market cap of $4.60 billion, a P/E ratio of -20.37 and a beta of 1.18. Dianthus Therapeutics has a 12 month low of $16.64 and a 12 month high of $96.50. The stock’s 50 day moving average is $87.29 and its two-hundred day moving average is $63.58.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Equities research analysts forecast that Dianthus Therapeutics will post -3.82 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.